Theravance Biopharma (NASDAQ:TBPH) Rating Increased to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded shares of Theravance Biopharma (NASDAQ:TBPH) from a hold rating to a strong-buy rating in a research note published on Sunday morning.

TBPH has been the subject of several other research reports. TD Cowen raised their price objective on shares of Theravance Biopharma from $13.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, March 23rd. B. Riley Financial reiterated a “neutral” rating and issued a $14.00 target price (down from $28.00) on shares of Theravance Biopharma in a report on Wednesday, March 4th. Oppenheimer cut shares of Theravance Biopharma from an “outperform” rating to a “market perform” rating in a report on Thursday, March 5th. HC Wainwright lifted their price target on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a “buy” rating in a research report on Monday, March 2nd. Finally, Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a report on Tuesday, March 24th. Two research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, Theravance Biopharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

Theravance Biopharma Price Performance

Shares of TBPH stock opened at $15.08 on Friday. The stock has a 50-day simple moving average of $17.49 and a 200 day simple moving average of $16.93. The stock has a market capitalization of $776.47 million, a P/E ratio of 7.43 and a beta of 0.17. Theravance Biopharma has a fifty-two week low of $7.90 and a fifty-two week high of $21.03.

Insider Buying and Selling

In other Theravance Biopharma news, SVP Rhonda Farnum sold 31,067 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $13.96, for a total value of $433,695.32. Following the completion of the transaction, the senior vice president directly owned 232,699 shares in the company, valued at $3,248,478.04. This trade represents a 11.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 6.90% of the company’s stock.

Institutional Investors Weigh In On Theravance Biopharma

Several hedge funds have recently made changes to their positions in the company. Quarry LP purchased a new position in Theravance Biopharma during the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd lifted its holdings in shares of Theravance Biopharma by 107.4% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock valued at $40,000 after purchasing an additional 1,411 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Theravance Biopharma by 26.5% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 515 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in shares of Theravance Biopharma by 18.5% in the second quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after buying an additional 781 shares during the period. Finally, CIBC Private Wealth Group LLC grew its holdings in shares of Theravance Biopharma by 20,269.6% during the third quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 4,662 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Company Profile

Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.